Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Social stress induces autoimmune responses against the brain

Shimo Y. et al, (2023), Proceedings of the National Academy of Sciences, 120

Ketamine for Major Depressive Disorder.

Costi S., (2023), Curr Top Behav Neurosci

Preliminary Evaluation of a Web-Based International Journal Club for Ketamine in Psychiatric Disorders: Cross-Sectional Survey Study.

Lindner JR. et al, (2023), JMIR Med Educ, 9

Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression.

Anand A. et al, (2023), N Engl J Med, 388, 2315 - 2325

Preliminary Evaluation of a Web-Based International Journal Club for Ketamine in Psychiatric Disorders: Cross-Sectional Survey Study (Preprint)

Lindner JR. et al, (2023)

Peripheral immune-derived matrix metalloproteinase promotes stress susceptibility

Russo S. et al, (2023)

A randomized pilot study of the prophylactic effect of ketamine on laboratory-induced stress in healthy adults.

Costi S. et al, (2023), Neurobiol Stress, 22

Exaggerated amygdala response to threat and association with immune hyperactivity in depression

Boukezzi S. et al, (2022), Brain, Behavior, and Immunity, 104, 205 - 212

The Potential of KCNQ Potassium Channel Openers as Novel Antidepressants

Costi S. et al, (2022), CNS Drugs, 36, 207 - 216

Whole blood transcriptional signatures associated with rapid antidepressant response to ketamine in patients with treatment resistant depression

Cathomas F. et al, (2022), Translational Psychiatry, 12

Treatment-resistant depression: Therapeutic options when first-line treatments fail

Wigg C. and Costi S., (2022), BJPsych Advances, 28, 4 - 8

Ketamine as a prophylactic resilience-enhancing agent.

Evers AG. et al, (2022), Front Psychiatry, 13

Neuroimaging correlates and predictors of response to repeated-dose intravenous ketamine in PTSD: preliminary evidence

Norbury A. et al, (2021), Neuropsychopharmacology, 46, 2266 - 2277

Peripheral immune cell reactivity and neural response to reward in patients with depression and anhedonia

Costi S. et al, (2021), Translational Psychiatry, 11

Impact of the KCNQ2/3 Channel Opener Ezogabine on Reward Circuit Activity and Clinical Symptoms in Depression: Results From a Randomized Controlled Trial

Costi S. et al, (2021), American Journal of Psychiatry, 178, 437 - 446

A Randomized Controlled Trial of Repeated Ketamine Administration for Chronic Posttraumatic Stress Disorder

Feder A. et al, (2021), American Journal of Psychiatry, 178, 193 - 202

Effects of the KCNQ channel opener ezogabine on functional connectivity of the ventral striatum and clinical symptoms in patients with major depressive disorder

Tan A. et al, (2020), Molecular Psychiatry, 25, 1323 - 1333

Ketamine normalizes subgenual cingulate cortex hyper-activity in depression

Morris LS. et al, (2020), Neuropsychopharmacology, 45, 975 - 981

Lithium continuation therapy following ketamine in patients with treatment resistant unipolar depression: a randomized controlled trial

Costi S. et al, (2019), Neuropsychopharmacology, 44, 1812 - 1819

Ultra-high field MRI reveals mood-related circuit disturbances in depression: a comparison between 3-Tesla and 7-Tesla

Morris LS. et al, (2019), Translational Psychiatry, 9

Load More

Include forthcoming?